Takeda's acquisition of Shire

At the beginning of the year, several months ahead of plan, Takeda's acquisition of Shire was completed. Acquisition makes Takeda one of the global leading value-based biopharmaceutical companies, focused on research and development of innovative medicines, and highly dedicated to patient’s better health for brighter future. By joining these two companies together, Takeda has continued with over 230 years cherished corporate philosophy named takedism, based on the values ​​of ethics, fairness, congeniality and persistence, which is the base of everyday work.

Takeda’s R&D efforts are focused on its four therapeutic areas of Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. With targeted R&D investment committed to Plasma-Derived Therapies (PDT) and Vaccines, Takeda is like four biotech companies in one according to words of CEO Cristopher Weber. Takeda's strengthened, highly innovative R&D engine enables the company to have a more global, robust and modality-diverse pipeline as well as to focus on breakthrough innovation.

Takeda seriously understands its social responsibility, which is primarily the development of open business relationships with healthcare providers, patient associations, government organizations and pharmaceutical industry bodies. Together with the global community, Takeda has a vision of providing healthcare for all with a strong focus on education that will help prevent and mitigate illness.